Sandborn William J. 4
4 · Ventyx Biosciences, Inc. · Filed Sep 1, 2023
Insider Transaction Report
Form 4
Sandborn William J.
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2023-08-31$14.85/sh+11,900$176,715→ 60,289 total - Sale
Common Stock
2023-08-31$33.64/sh−11,900$400,354→ 48,389 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-08-31−11,900→ 664,300 totalExercise: $14.85Exp: 2032-05-09→ Common Stock (11,900 underlying)
Holdings
- 24,194(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2022.
- [F2]Represents the weighted average share price of an aggregate total of 11,900 shares sold in the price range of $33.35 to $34.1159. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the shares subject to the option will vest on the one year anniversary of the Vesting Commencement Date (as defined below), and 1/48th of the shares subject to the option will vest ratably each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 9, 2022.